XWELL Q1 revenue falls to $7.0M; net loss $4.7M; CDC contract extended 3 years

XWELL, Inc.

2025-Q1 EPS reported -$1.00 revenue$7,023,000

Revenue $7.0M, down 19% from $8.7M YoY; net loss attributable $4.7M vs $2.5M.
Cost of sales down 6% to $5.7M; operating expenses down 11% to $4.5M; operating loss $3.2M.
Closed $4M private placement (Series G preferred + warrants) in Jan 2025; cash $3.7M, marketable securities $7.3M, no debt.
Secured 3-year extension of CDC Traveler-based Genomic Surveillance Program (TGS) in March 2025.
Plans to acquire medical spas in Orlando, Dallas, Salt Lake City; new XWELL location at NYC Penn Station mid-2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.